July 26, 2021

Our CEO, Franco Lori, has been recently interviewed by Global Business Reports (GBR)

Our CEO, Franco Lori, has been recently interviewed by Global Business Reports (GBR), presenting ViroStatics’ programs on antiviral and anticancer compounds as well as our tailored services to test drugs, disinfectants and devices against SARS-CoV-2.

About GBR

Headquartered in Singapore and with offices in Istanbul, Global Business Reports (GBR) was established in 2001 in order to provide up to date and first hand information for global business decision makers.In an age where cross boundary trade and investment and the globalization process are the driving factors for latest businesses, information is crucial. Precise sectorial reports help companies understand and expand their markets, improve their sourcing chain, target their investments and discover the trends affecting their industry around the world.

June 29, 2021

ViroStatics’ Services have been peer-reviewed. Article published in Precision Nanomedicine

This Technical Note describes the background, instrumentation, and expertise of ViroStatics to test drugs, materials, or devices against various strains of SARS-CoV-2.

Precision Nanomedicine (PRNANO) is a platinum open access, peer-reviewed international journal (E-ISSN:2639-9431), the official journal of the European Foundation for Clinical Nanomedicine (CLINAM).

The journal is endorsed by the European Society for Nanomedicine (ESNAM), by the International Society for Nanomedicine (ISNM, Basel), and supported by the British Society for Nanomedicine.

June 7, 2021

ViroStatics among the best Italy-based Pharmaceutical companies Best

Companies were selected across the size spectrum from cutting edge startups to established brands.

Startups and companies listed were chosen for exceptional performance in one of these categories:

  • Innovation
  • Growth
  • Management
  • Societal impact

March 2, 2021

ViroStatics has received the label InvestHorizon – Accelerated

The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.

This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.

InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.

November 25, 2020

ViroStatics awarded with H2020 Seal of Excellence (to view the document please click here Seal of Excellence 2020)

Project proposal 970239 TOSCA “A Novel CDK4/6/9 Inhibitor for the Treatment of Aggressive Cancers”

Horizon 2020’s SME Instrument (grant only and blended finance) call H2020-EIC-SMEInst-2018-2020 (H2020-EIC-SMEInst-2018-2020-3) of 7 October 2020 in the area of EIC-SMEInst-2018-2020 SME instrument

October 30, 2020

ViroStatics selected by Meet in Italy for Life Sciences

ViroStatics is among the finalists to pitch its presentation in virtual mode.

Meet in Italy for Life Sciences is the leading national matchmaking and update event on Life Sciences.
Health-related innovations are among the key elements that influence the progress of mankind, the environment in which we live, and our wellbeing. Speaking about health, therefore, does not mean simply speaking about investments and costs, but rather about an absolute value that sees in technological innovation and scientific research the fundamental elements of growth.

ViroStatics has been selected to present its business proposal refined through tailored sessions with life sciences expert, coaches, investors, that allowed unleashing its full potential and improved its business approach and the communication of its innovation value.

July 4, 2020

ViroStatics is now fully equipped to test any compound (small molecule and/or biologic) against SARS-CoV-2

ViroStatics scientists have >30 years experience testing antivirals, including double and triple drug combinations, both in the laboratory and in the clinics, leading to the description of the first functional cure of an HIV infected patient (the Berlin Patient, New England Journal of Medicine, 1999).

If you are interested to have any compound tested by us, please contact ViroStatics CSO, Davide De Forni, at

March 19, 2020

ViroStatics is engaged to fight against COVID-19

The Coronavirus pandemic (COVID-19) is in everyone’s mind and heart. We assure you that we are putting all our forces into action to fight it. Help us identifying with our research as many drugs as possible to be made immediately available to our doctors. Help our search.


Interview (in Italian): TV Parma

Article (in Italian): Panorama

May 8, 2019

ViroStatics awarded with H2020 Seal of Excellence (to view the document please click here Seal of Excellence 2019)

“TOSCA” project proposal, aiming at reaching clinical readiness for VS2-370, a novel oral CDK4/6/9 inhibitor developed for the treatment of aggressive tumors (breast, lung, pancreas, haemato-oncology), for out-licensing or M&A with a Pharmaceutical Company, has been judged as a high quality proposal following highly competitive evaluation process by an international panel of independent experts and has been therefore awarded with the SEAL OF EXCELLENCE within the Horizon 2020’s SME instrument Phase 2 call H2020-EIC-SMEInst-2018-2020. Horizon 2020 is the biggest EU Research and Innovation programme ever for breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.

April 30 – May 1, 2019

BioTrinity, London, UK

ViroStatics will be attending the partnering event BioTrinity. BioTrinity, in its 13th year, is Europe’s leading Biopartnering and Investment conference, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations. For the highlights, please visit this video.

Davide De Forni, CSO of ViroStatics, will attend the event.

November 5-7, 2018

BIO-EUROPE 2018, Copenhagen, Denmark

ViroStatics will be attending the partnering event at BIO-Europe 2018 and welcome the opportunity to discuss our out-licensing program on CDK 4/6/9 inhibitors against cancers and viral diseases. In addition, we have scheduled meetings with potential customers interested in ViroStatics’ drug discovery outsourcing services.

Franco Lori, CEO of ViroStatics, will attend the event.

July 3, 2018

ViroStatics has been certified by AIFA as Phase I Clinical Trial Laboratory

In 2015, the Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA) issued the Determination 809/2015 with new requirements for phase I clinical trials. The new AIFA Determination imposes a certified organizational model on units and laboratories involved in phase I trials.

ViroStatics is now inserted in the list of certified Phase I Clinical Trials sites available on AIFA website at this link

October 11-13, 2017

Meet In Italy for Life Sciences and Italian Healthcare Venture Forum 2017, Turin, Italy

ViroStatics has been selected to present at the Italian Healthcare Venture Forum 2017, taking place on October, 11-12th 2017 at the Torino Incontra Congress Centre in Turin, Italy. Our company is among the top 20 companies selected by the Selection Committee out of more than 70 innovative companies that have applied for the event.

ViroStatics will be also attending the partnering event Meet in Italy for Life Sciences.

The event stretches over three intensive (net)working days, during which business meetings, networking activities, pitching sessions, thematic workshops and, at the end, a convention on the life sciences key trends and innovation strategies will take place.

The event offers high visibility and opportunities for businesses and networking, creating dedicated dialogues between national and international, public and private stakeholders, by networking research-driven innovation.

July 30, 2017

ViroStatics has successfully concluded the Project “Thunder” under Horizon 2020 dedicated SME Instrument

“Thunder” project represents a feasibility study about the development of the innovative CDK inhibitor VS2-370 with a dual pronged applicability: treats certain HIV-associated cancers while simultaneously purging the HIV reservoirs which continue to threaten individuals suffering from AIDS. This dual pronged approach provides a clear pathway for regulatory approval which is not available to those drugs under development which are HIV specific. We achieved proof of concept demonstrating activity of the drug in vitro and in vivo in a relevant model of HIV-associated tumors (i.e Non-Hodgkin Primary Effusion Lymphoma, PEL).

During the project we have completed the documentation on VS2-370 intended for Pharmas and reached out to 34 likely potential future oncology-oriented partners with the primary goal to educate them ahead of a formal process after further pre-clinical studies. We have received positive feedbacks and agreed to proceed with the development of the product by completing the studies necessary for the Investigational Medicinal Product Dossier to allow the Pharma partner to run the first-in-man clinical trial.

April 26-27, 2017

Startup Olé 2017, Salamanca, Spain

Being a Seal of Excellence holder, ViroStatics has been selected to attend the event Startup Olé in Salamanca.

Startup Olé includes a Startup Fair, a Pitching Competition and Curated Matchmaking with relevant corporates and investors and private networking. SMEs will have the opportunity to present their business, pitch to investors, attend workshops, network and much more.

Davide De Forni, CSO of ViroStatics, will attend the conference.

March 20-22, 2017


ViroStatics will be attending the partnering event at BIO-Europe Spring and welcome the opportunity to discuss our out-licensing program on CDK 4/6/9 inhibitors against cancers and viral diseases. In addition to back-up compounds for oncology and HIV, ViroStatics has a pipeline of novel candidates that have the potential ability to treat hepatitis B virus, varicella zoster virus and Epstein-Barr virus.

Franco Lori, CEO of ViroStatics, will attend the event.

December 12, 2016

Thunder Project selected for Phase I SME instrument by the European Community

ViroStatics gets EU funding under Horizon 2020, the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020), within the SME Instrument Topic: SMEInst-03-2016-2017 — Dedicated support to biotechnology SMEs closing the gap from lab to market.

The project aim is to perform a feasibility study for the development of the innovative drug VS2-370 that targets both HIV-associated cancer and has the potential to purge the viral reservoir. ViroStatics strategy is to develop the potent and selective cyclin-dependent kinase inhibitor VS2-370 through the well established pathway of oncology drugs, then to expand the indication to the HIV cure.

June 29, 2016

Jadranka Rogan, MD, PhD joined the Team as Head of Clinical Development

She brings expertise in clinical oncology. In her 25 years service to Pharma Industry she covered positions of Medical director for Farmitalia Carlo Erba office for Eastern Europe, CSC Pharmaceuticals and Cyathus Exquirere, Vienna. Also she ran the Regulatory affairs office and Pharmacovigilance for CSC Pharmaceuticals and was Qualified person for Pharmacovigilance (EUQPPV) for Cyathus Exquirere. Currently, she is CEO of Inphares GmbH, a network of professionals with expertise in diverse fields of pharmaceutical research and development.

June 21, 2016

ViroStatics awarded with H2020 Seal of Excellence (to view the document please click here Seal of Excellence 2016)

The project proposal THAMAR related to the development of our CDK inhibitor to target HIV-associated malignancies and to purge viral reservoir submitted under the Horizon 2020’s SME instrument phase 1 call H2020-SME Inst-2016-2017 in the area of Dedicated support to biotechnology SMEs closing the gap from lab to market by ViroStatics following evaluation by an international panel of independent experts was successful in a highly competitive evaluation process as an innovative project proposal.